Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.

All News

NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
BiotechnologyCompany Update

NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements

May 11, 2023 9:00 AM

Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain TumorsRecent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at World Orphan Drug CongressCLEVELAND, OH / ACCESSWIRE / May 11, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that Dr. Christopher Wheeler, Ph.D., President,...

Read more
cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
BiotechnologyCompany Update

cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial

May 11, 2023 9:00 AM

DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations.DehydraTECH-CBD has demonstrated exceptional safety and tolerability and a sustained decrease in blood pressure.KELOWNA, BC / ACCESSWIRE / May 11, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that batch manufacturing of...

Read more
The BWB Awards at Biotech Week Boston Returns for a Celebratory Gala September 18th, 2023
BiotechnologyAwards

The BWB Awards at Biotech Week Boston Returns for a Celebratory Gala September 18th, 2023

May 10, 2023 1:30 PM

BOSTON, MA / ACCESSWIRE / May 10, 2023 / The BWB Awards at Biotech Week Boston returns for a night of dinner, drinks, entertainment, and the recognition of the top individuals, companies, and organizations in the life sciences community. Since 2018, the Awards at the Biotech Week Boston festival have been bringing together the faces and names that make the Boston community the beating heart of the biotech world. Join 150+ leaders across the...

Read more
Longwood Healthcare Leaders to Convene Top Biotech and Pharmaceutical Leaders at MIT Koch Institute
BiotechnologyConferences

Longwood Healthcare Leaders to Convene Top Biotech and Pharmaceutical Leaders at MIT Koch Institute

May 10, 2023 7:00 AM

BOSTON, MA / ACCESSWIRE / May 10, 2023 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of off-the-record discussions and networking at its Spring MIT Longwood Healthcare Leaders Conference, co-hosted by Nobelist and Alnylam/Biogen Co-Founder Phillip Sharp, Ph.D., at The Koch Institute at MIT June 7-8, 2023. Longwood Healthcare Leaders The industry-leading conference focuses on a...

Read more
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
BiotechnologyEarnings

Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates

May 10, 2023 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDTEnrollment for elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to progress with topline clinical data anticipated by mid-2024; successful safety review completed for 10 mg dose cohortPRS-220, inhaled Anticalin protein for idiopathic pulmonary fibrosis (IPF), continues in Phase 1 study with topline results expected H2 2023PRS-400, inhaled...

Read more
Lifeloc Reports First Quarter 2023 Results
BiotechnologyEarnings

Lifeloc Reports First Quarter 2023 Results

May 9, 2023 4:52 PM

WHEAT RIDGE, CO / ACCESSWIRE / May 9, 2023 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the first quarter ended March 31, 2023.First Quarter Financial HighlightsLifeloc posted quarterly net revenue of $2.165 million resulting in a quarterly net loss of $(54) thousand, or $(0.02) per diluted share. These results...

Read more
Scailyte Announces Jan Lichtenberg, CEO at inSphero, as a Member of the Board of Directors
BiotechnologyManagement Changes

Scailyte Announces Jan Lichtenberg, CEO at inSphero, as a Member of the Board of Directors

May 9, 2023 3:00 PM

BASEL, SWITZERLAND / ACCESSWIRE / May 9, 2023 / Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is proud to announce the appointment of Jan Lichtenberg to its Board of Directors. Scailyte announces Jan Lichtenberg, CEO at InSphero, as a member of the Board of Directors Scailyte announces Jan Lichtenberg, CEO at InSphero, as a member of the Board of Directors Jan Lichtenberg, Ph.D., is Co-Founder...

Read more
L-Nutra Launches First-of-Its Kind Longevity Nutrition Product Line Called 'ProLon EveryDay'
BiotechnologyProduct Announcements

L-Nutra Launches First-of-Its Kind Longevity Nutrition Product Line Called 'ProLon EveryDay'

May 9, 2023 9:00 AM

First product to the market from the 'ProLon EveryDay' product line is the L-Spread, rich in Longevity Nuts sourced from Italy's Longevity Area and formulated based on the Longevity Diet by Dr. Valter Longo.LOS ANGELES, CA / ACCESSWIRE / May 9, 2023 / L-Nutra Inc., the world's leading nutrition technology company pioneering the discovery and commercialization of novel nutrition products that impact both the body's metabolism and cellular...

Read more
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
BiotechnologyCompany Update

Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting

May 9, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting held in Chicago on June 2-6, 2023. The poster...

Read more
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
BiotechnologyConference Call

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

May 8, 2023 5:30 PM

MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2023 after the stock market close on Monday, May 15, 2023. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate...

Read more
Applied Energetics Announces Appointment of Dr. Stephen W. McCahon, as Chief Science Officer
BiotechnologyCompany Update

Applied Energetics Announces Appointment of Dr. Stephen W. McCahon, as Chief Science Officer

May 8, 2023 9:55 AM

Dr. McCahon, co-founder of the Company, brings more than three decades of experience as a scientific researcher, technology developer, and pioneer innovating and translating optical technology to applications spanning the directed energy spectrum.TUCSON, AZ / ACCESSWIRE / May 8, 2023 / Applied Energetics, Inc. (OTCQB:AERG), a leader in the advancement of ultrashort pulse laser (USPLTM), announced today that Dr. Stephen W. McCahon, age 63, has...

Read more
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
BiotechnologyCompany Update

Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress

May 8, 2023 8:00 AM

MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting updated results for treatment-naïve patients from the Phase 1b study of gedatolisib, a pan-PI3K/mTOR inhibitor, in combination with palbociclib and letrozole in women with HR+/HER2- advanced breast cancer (ABC). A...

Read more
Alia Therapeutics names Letizia Goretti as Chief Executive Officer
BiotechnologyManagement Changes

Alia Therapeutics names Letizia Goretti as Chief Executive Officer

May 5, 2023 4:00 AM

MILAN, ITALY / ACCESSWIRE / May 5, 2023 / Alia Therapeutics, a Trento-based start-up specializing in innovative treatments for rare genetic diseases through next-generation gene editing technology, announced the appointment of Letizia Goretti as Chief Executive Officer (CEO) and Board Director, effective immediately. Letizia, who is joining Alia from Johnson & Johnson, has more than 25 years of international experience in life sciences. She...

Read more
Chi Botanic Inc. Awarded Competitive USDA SBIR Phase I Grant for Plant Cell-Cultured Vanilla
BiotechnologyAwards

Chi Botanic Inc. Awarded Competitive USDA SBIR Phase I Grant for Plant Cell-Cultured Vanilla

May 4, 2023 9:00 AM

Small Business Innovative Research Program Provides $175,000 in Funding for Chi Botanic's Sustainable Vanilla TechnologyALAMEDA, CA / ACCESSWIRE / May 4, 2023 / ChiBotanic Inc. is pleased to announce that its research and commercialization project for a new cell-cultured Vanilla 2.0 technology for a plant-based full-spectrum natural vanilla flavor has been awarded a highly competitive Small Business Innovative Research (SBIR) Phase I Award of...

Read more
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

May 4, 2023 8:35 AM

Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertiseFRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Reid P....

Read more
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
BiotechnologyCompany Update

Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)

May 4, 2023 8:00 AM

BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful safety review of the 10 mg dry powder dose safety cohort from the ongoing multi-center, placebo-controlled phase 2a study of dry powder...

Read more
Biomed Industries, Inc. Offers to Acquire Quince Therapeutics, Inc.
BiotechnologyMergers and Acquisitions

Biomed Industries, Inc. Offers to Acquire Quince Therapeutics, Inc.

May 3, 2023 9:00 AM

Offer is at $2.50 per share, or 60% premium to yesterday's closing priceThe offer consists of $1.55 in cash per share and $1.00 in shares of Biomed Industries, Inc.SAN JOSE, CA / ACCESSWIRE / May 3, 2023 / Earlier today Biomed Industries, Inc. issued a letter to the Board of Directors of Quince Therapeutics, Inc. (NASDAQ:QNCX).The letter described a proposal to acquire all the company's common stock for $2.50 pershare in cash and stock of Biomed...

Read more
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

May 3, 2023 8:35 AM

Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planningFRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Scott N. Cullison to...

Read more
Longwood Fund Closes $180 Million Fund to Create and Invest in Early-Stage Biotechnology Companies
BiotechnologyFinancing

Longwood Fund Closes $180 Million Fund to Create and Invest in Early-Stage Biotechnology Companies

May 3, 2023 7:00 AM

BOSTON, MA / ACCESSWIRE / May 3, 2023 / Longwood Fund, a venture capital firm dedicated to creating and investing in science-based companies that develop novel solutions to treat important unmet medical needs, today announced the closing of its sixth fund with $180 million committed to the fund and related vehicles, representing the firm's largest fund to date. Longwood Fund General Partners Christoph Westphal and David Steinberg "We are...

Read more
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
BiotechnologyEarnings

Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023

May 2, 2023 4:30 PM

BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host its first quarter 2023 investor call on Wednesday, May 10, 2023, at 8:00 AM EDT to discuss financial results and provide a corporate update.To...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?